The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants.
about
Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactionsRisk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant alleleThe influence of UGT polymorphisms as biomarkers in solid organ transplantationStructure and Protein-Protein Interactions of Human UDP-GlucuronosyltransferasesPopulation pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patientsEffects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritisPolymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancerSorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patientDimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activitiesMicrosomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic ClearanceThe effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liverEnantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzymeSteady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort studyDiabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patientsGlucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.Pharmacokinetic principles of immunosuppressive drugs.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsUGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipientsIndividualization of mycophenolate mofetil dose in renal transplant recipients.Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy.Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability.Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant PatientsFunctional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene.Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity.Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients.Human clearance prediction: shifting the paradigm.Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.
P2860
Q24337041-A182105F-41B6-4512-AAAE-A1E9B31125C7Q24595480-A4EEA7D9-5FB0-478C-BEA7-20DEE4647B3DQ27009825-63619795-5252-4423-B8CC-C7FCE58448D8Q28071266-572653D6-C8FB-47E4-B814-78FF44CF06FFQ28272907-7E68CE21-23FF-47AF-9951-A1CC457B26AFQ28285877-8CF7FF9A-590A-4698-9D75-5661D5B7A6A4Q28487071-CCE0D213-244D-4BB5-B81E-AEA9F2CD96ECQ28538514-54237F12-3E1F-4085-8D46-59B6AE224549Q28834515-08B873B2-E44B-4220-99B1-CEF064AF440FQ33588394-EC814A7B-3949-4DB0-800F-04EAEDEC2BF6Q33724160-FC3715B0-0020-415C-BB0D-08DC623AF25DQ34211851-BAF8B342-BA7B-4BBE-A188-708C9C4DCCF5Q34335228-81263259-431D-4AED-BEA8-129E18F9E5D8Q34614033-3B744210-BA98-4A41-96D5-7A0E6A4B135CQ34702634-F7792DDD-41FF-4152-96F4-4252E3367FA7Q34947658-AB6D5448-614B-485C-8293-A520977CC654Q34984788-E0A14C58-B37B-4708-A430-56CD39C56462Q35008045-F3C40840-B849-457F-A523-42C28E791EECQ35578549-070928D9-3BD8-4A16-8509-EE51077BE1F3Q35745226-AF5BC5DB-FCC0-41D8-8140-0F37693732ADQ35846898-F48C84E6-F308-438E-9824-AF54EF08EF5BQ36006086-25AC7AF9-DECB-4AB0-837E-722D9ECA8B35Q36018556-63AF3684-5A85-4B38-9282-B1E1C52B3E6BQ36400272-C9D5E9F6-E364-4661-8741-C2ECD02E5C1AQ36407345-51A47EC3-8E2C-4FA4-BC59-1145469866E4Q36544981-654122E3-D527-411F-9C0D-C5152CE4AE31Q36544988-C5BE89F8-D63B-422E-9A6C-A451913EA18AQ36629233-0DBE5D83-5923-48BF-8D84-2973732FA86BQ36725226-7BA4C307-1B39-499E-AF78-DAA96607D17BQ36777485-75401B4B-A080-454F-AFF6-6BD982CAE2DEQ36788423-BACAAF56-FFCF-4AA2-829A-E025F5D756CDQ36792638-8C049B02-D382-4229-A509-81AE714F8E02Q36959519-8FB44B2B-7088-42D9-B062-EB95A72B5692Q37157896-F17F4CCC-570C-4A85-BB7B-D726E97678C1Q37268535-B32292DD-F8AA-453F-BA3A-F05DC653A8FDQ37402758-3FE7CFE4-BDAC-4494-B287-8005E3A8CEF5Q37422055-654EB65A-B7CE-45C4-A748-64CF3286D37AQ37452521-BBE0EFE2-B680-403F-A6CB-C51C19BE7BB0Q37554400-71A9F162-1F05-4940-B29B-9ECEBB410E09Q37646842-55769933-0C62-4939-9BF1-C9735D52906E
P2860
The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The main role of UGT1A9 in the ...... naturally occurring variants.
@en
The main role of UGT1A9 in the ...... naturally occurring variants.
@nl
type
label
The main role of UGT1A9 in the ...... naturally occurring variants.
@en
The main role of UGT1A9 in the ...... naturally occurring variants.
@nl
prefLabel
The main role of UGT1A9 in the ...... naturally occurring variants.
@en
The main role of UGT1A9 in the ...... naturally occurring variants.
@nl
P356
P1476
The main role of UGT1A9 in the ...... naturally occurring variants.
@en
P2093
Olivier Bernard
P304
P356
10.1124/DMD.32.8.775
P577
2004-08-01T00:00:00Z